New Research Reports

Aurionpro Solutions: From Services Player to Global IP-Led Powerhouse

CCL Products (India) Ltd., established in 1994, is a leading global coffee manufacturer and exporter with operations across India and a presence in over 100 countries. Its diversified product portfolio includes spray-dried and freeze-dried coffee, liquid concentrates, roast and ground coffee, coffee beans, and premixed blends. The company's international footprint is supported by key subsidiaries,...

years will weigh on near-term margins but aim to deliver sustainable cost efficiencies and long-term growth. Rising input costs could pressure margins in the coming quarters, though selective pricing and supply-chain optimization should partly offset the...

We initiate coverage of Granules with BUY and SOTP-based Mar-27 TP of Rs800 (implied target EV/EBITDA of ~12x; ~30% upside). Granules fits into our framework of backing companies with a smaller US base + a US portfolio construct with strong near-term growth visibility.

EPL has announced a merger of Indovida (a rigid packaging company) which allows Indorama Ventures to become the majority shareholder (with a 51.8% stake) in the merged entity.

Vinati Organics Ltd. (VOL) enjoys global leadership in two specialty chemicals, with a market share of 70% in IBB (isobutyl benzene) and 80% in ATBS (2Acrylamindo 2-Methylpropane Sulfonic Acid). In 9MFY26, revenue remained flat YoY, primarily due to lower realizations driven...

*over or under performance to benchmark index PVR Inox is positioned for a recovery-led exit from FY26, with Q4FY26 already witnessing a blockbuster slate led by the second instalment of the Dhurandhar franchise, alongside select Bollywood and regional releases, driving significant box-office momentum. FY27 is expected to outperform FY26, supported by a highly anticipated and diverse content slate across languages, translating into sustained growth in footfalls and revenues. Beyond the near term, record box-office collections in CY25 reinforce a clear consumer preference for theatrical viewing over OTT. Management's focus on capital-light expansion, screen rationalisation and...

EPL and Indovida (a leading global rigid PET packaging company and subsidiary of Indorama Ventures Ltd) have signed definitive agreements to merge, creating a ~USD1b revenue entity with a combined valuation of ~USD2b.

Bain Capital will invest Rs.4,385cr to acquire joint control and promoter status in Manappuram Finance, with all regulatory approvals, including from the RBI, now in place. Post the preferential allotment and open offer, Bain's stake is expected to range between 18% and 41.7%, while the existing promoters' holding will dilute to around 28.9%. The transaction is expected to close by March 31, 2026.The partnership with Bain Capital adds strategic depth, enhancing governance standards, capital flexibility, and execution capabilities as the company enters a stabilization phase. While the recovery is likely to be gradual, operating metrics are expected to improve over time. Accordingly, we upgrade our rating to Hold, with a target...

We interacted with the management of Kajaria Ceramics (KJC), wherein they highlighted a gradual recovery in Q4FY26 led by 78% volume growth, supported by channel destocking and normalization of operations. Supply disruptions in Morbi (gas issues and shutdowns) have created a market share gain opportunity, aided by low...

Current exposure in the Middle East (ME) remains low (~10% of overall orderbook). The management sees potential revenue impact of USD20-30mn in Q4FY26 due to supply-related challenges for the Power T&D business.

pick up in Q4FY26 with a target of ~Rs 23bn (vs. Rs 17.2 bn in Q3FY26) aided by improved salesforce and tech integration. It is targeting ~ Rs 70bn of disbursements in FY27 with an AUM growth of ~18% in FY27E and ~20% in FY28E. Growth is expected to be driven by i) branch expansion (~50 additions in FY27,...

Sagility Ltd. is a healthcare-focused, technology-enabled solutions provider primarily serving U.S. health insurers (payers), along with hospitals, physicians, and medical device companies (providers). Headquartered in Bengaluru, the company operates 33 delivery centers across India, the U.S., and other global markets. In Q3FY26, ~90% of its revenue...

Create domain specific agentic AI solutions to expand TAM Sustain revenue momentum while maintaining margins We attended Sagility's Investor Day, where management outlined how US healthcare policy changes and AI adoption are reshaping its business, and how the company is turning these headwinds into growth opportunities. Policy-driven margin pressures on payer clients are accelerating the shift toward cost-saving outsourcing, where Sagility's human in the loop agentic solutions, built on two decades of domain expertise across both payers and providers, can reduce client costs and effort by ~30%...

Time Technoplast’s (TIME) business operations remain broadly stable despite ongoing conflicts in parts of the Middle East (~11% of revenue). Its B2B industrial packaging business (~65% of revenue) has moderate growth but a very stable business profile.

The company reiterated its $400mn revenue target for FY28, supported by over 60 pending low-competition U.S. launches, while management remains constructive on other regulated markets, where an expanding product portfolio and new customer additions are expected to drive stronger growth and eventually scale these markets to revenue levels comparable with the U.S. business....

Sagility hosted its first analyst meet (on 25th Mar’26). It highlighted that AI continues to be a key growth driver, woven into most of its solutions and platforms.

Growth strategies are clearly anchored around: cost transformation driven by demand from US payers; capability-led differentiation, including AI.

Kalpataru Projects International (KPIL), during its analyst meet, highlighted a strong addressable market for both its T&D and B&F segments over the next 2-3 years, providing clear visibility for order inflows as well as execution.

Revenue growth was flat YoY, primarily due to R&D project delays. EBITDA grew by 8% YoY, margins expanded by 80bps YoY to 31.7%, supported by higher margins domestic order execution. Reported PAT declined by 4.5% YoY, despite strong operating performance, as higher depreciation and lower JV profit share offset EBITDA gains....